GCP & Regulatory Compliance
This section covers the compliance backbone that governs how a clinical trial is actually conducted once it is underway: the principles investigators and sponsors are held to, and the mechanisms used to verify those principles are being followed. Good Clinical Practice (GCP) is the internationally recognized ethical and scientific quality standard for designing, conducting, recording, and reporting trials involving human subjects. It is codified through the ICH E6 guideline, now in its E6(R3) revision, which places greater emphasis on quality-by-design and risk-based, proportionate oversight than earlier versions did. Beyond the standard itself, this cluster addresses how compliance is verified and enforced in practice. Regulatory authorities inspect and audit investigator sites, sponsors, and contract research organizations to confirm that trial conduct matches both the protocol and applicable regulation. In the United States, the FDA's Bioresearch Monitoring (BIMO) program is the primary vehicle for this oversight, and a Form 483 is the formal mechanism by which FDA investigators document objectionable conditions found during an inspection, which sponsors and sites must then respond to and remediate. For a research administrator, this is the area governing informed consent processes, protocol adherence, investigator responsibilities, monitoring visit expectations, essential document maintenance, and the audit trail that demonstrates a trial was run to standard. It sits alongside, but is distinct from, the pre-market submissions and product-quality topics covered elsewhere in this cluster; here the focus is specifically the conduct of the trial itself and the inspection regime that checks it.
Guides
Mobile and Home Health Nursing Vendors in Decentralized Trials: Delegation, Credentialing, and Compliance
A practical guide to delegation, credentialing, and compliance mechanics specific to third-party mobile and home health nursing vendors performing protocol procedures in decentralized clinical trials.
Biobank Specimen Consent Models: Broad, Tiered, and Dynamic Consent Compared
A comparison of the three main biobank consent architectures — broad, tiered, and dynamic consent — and how each aligns with ISO 20387 biobank accreditation and GDPR-based data governance.
Major Protocol Deviation: What to Do and How to Report It to the IRB
When a major (important) protocol deviation happens, the study team’s response follows a specific sequence: address any immediate safety issue first, then document, classify, notify the sponsor and IRB, and close the loop with root-cause analysis and corrective action.
ClinicalTrials.gov Registration Requirements for Academic and Investigator-Initiated Trials
Who must register an investigator-initiated trial on ClinicalTrials.gov, how the “applicable clinical trial” test works, the 21-day registration and 12-month results deadlines under FDAAA 801/42 CFR Part 11, Form FDA 3674 and NIH’s Certification of Compliance, and what noncompliance actually costs an academic sponsor-investigator.
Sponsor Oversight of Delegated CRO Functions Under ICH E6(R3)
How ICH E6(R3)’s expanded sponsor-oversight framework applies when a sponsor delegates trial functions to a CRO: the Section 3.9 oversight requirements, quality-by-design and critical-to-quality factors, and what changes in practice from ICH E6(R2).
Full-Service CRO Monitoring: What Site Staff Should Expect (ICON and Peers)
A practical, site-coordinator-facing guide to how monitoring visits, communication channels, and escalation actually work when a sponsor outsources trial oversight to a full-service CRO such as ICON.
Challenges and Risks of Launching a Decentralized Clinical Trial
The data-quality, oversight, jurisdictional, equity, retention, and IRB risks a sponsor needs to assess before launching a decentralized or hybrid clinical trial.
The Informed Consent Process in Clinical Trials: Step by Step
A procedural, step-by-step walkthrough of the clinical trial informed consent process — from confirming eligibility through the consent conversation, documentation under 45 CFR 46.116/117, waiver of documentation, and re-consent triggers.
Common GCP Violations and How to Avoid Them
The GCP violation categories that recur most often in FDA and EMA inspections — informed consent deficiencies, protocol deviations, inadequate source documentation, drug/investigational-product accountability, and IRB non-compliance — with the root causes behind each and practical prevention measures.
The 4 Principles of Informed Consent
Autonomy, beneficence, non-maleficence, and justice — the Beauchamp and Childress bioethics principles as applied to the informed consent process, and how they relate to (and differ from) the Belmont Report’s three principles and the regulatory required elements.
Monitoring Visit Trip Report Writing: Structure, Findings, and Action Items
How to write a clinical trial monitoring visit trip report that holds up as a GCP audit-trail record: visit metadata, findings by category, and action items with due dates and responsible parties.
Risk-Based Quality Management (RBQM) in Clinical Trials
How quality-by-design and ICH E6(R2)’s risk-based framework build quality into a clinical trial from protocol design onward, rather than relying on downstream monitoring and audits to catch problems after the fact.
Clinical Trial Vendor Management: Selecting, Overseeing, and Auditing CROs, CTMS, and eClinical Vendors
A guide to sponsor-side vendor management in clinical trials: qualifying and selecting CROs, CTMS, and eClinical vendors; the oversight/quality agreement that is distinct from the CTA; the sponsor responsibilities that ICH E6(R2) Section 5.2 says cannot be delegated; vendor audits; and data-integration considerations across CTMS, EDC, and other eClinical systems.
Site Initiation Visit (SIV) Checklist: Regulatory, DoA, Training, IP, and Pharmacy Readiness
A practical, category-by-category site initiation visit checklist covering regulatory documents, the delegation-of-authority log, staff training records, investigational product accountability, and pharmacy readiness, grounded in ICH E6(R2).
GCP Inspections: What FDA and EMA Review, and How to Prepare
What FDA BIMO and EMA/national GCP inspectors review at a site or sponsor — source documents, informed consent, the TMF, and the delegation of authority log — plus the most common inspection findings and how sites and sponsors prepare.
Trial Master File Checklist: A Zone-by-Zone Guide
A practical trial master file checklist organized by the TMF Reference Model’s 11 zones, covering essential documents, sponsor TMF vs. Investigator Site File (ISF), and inspection readiness.
Delegation of Authority Log Template: Annotated Structure
An annotated delegation of authority (DoA) log template: the fields a compliant log needs under ICH E6(R2) 4.1.5, how to complete each one, and the errors monitors and FDA inspectors most often flag.
Conducting Investigator-Initiated Trials: FDA Regulations and GCP Requirements
A practical breakdown of what conducting an investigator-initiated trial (IIT) under FDA regulations actually requires: IND/IDE applicability, the sponsor-side and investigator-side obligations of 21 CFR Part 312 Subpart D, Form 1572, the delegation log, and where GCP and institutional infrastructure fit without shifting accountability.
Clinical Trial Auditing: Types, Process, and How It Differs From Monitoring
How clinical trial audits differ from routine monitoring and regulatory inspection, who conducts them, the main audit types, and how sponsor auditing relates to FDA’s BIMO program.
Clinical Trial Monitoring: Visit Types, Source Data Verification & the Monitoring Plan
What clinical trial monitoring actually involves: the CRA visit types (site initiation, routine/interim, close-out), what monitors check at a site including source data verification, the monitoring plan document, and how risk-based monitoring and CTMS fit into modern practice.
Decentralized Clinical Trials (DCTs): What They Are, FDA Guidance, and Key Components
What decentralized clinical trials (DCTs) are, FDA’s September 2024 final guidance, and the eConsent, remote monitoring, direct-to-participant shipment, and IRB considerations that distinguish them from traditional site-based trials.
Clinical Trials Ontario (CTO): The Streamlined REB Review Model
Clinical Trials Ontario (CTO) runs the Streamlined Research Ethics Review System (CTO STREAM), letting a single Qualified REB act as board of record for a multi-site Ontario trial instead of separate site-by-site ethics reviews.
Developing a Monitoring Plan for Investigator-Initiated Clinical Trials
How to build a risk-based monitoring plan for an investigator-initiated trial: who takes on the sponsor’s monitoring role, what the plan must contain under ICH E6, and resource-constrained approaches that still meet the GCP bar.
Good Documentation Practices (GDP) in Clinical Trials
Good documentation practices (GDP) means applying the ALCOA/ALCOA+ data-integrity principles to clinical trial source documents, case report forms, and essential documents so trial data can be trusted and reconstructed.
FDA Inspection Database: How to Search Inspection Classifications
How to search FDA’s public Inspection Classification Database and Data Dashboard, what NAI/VAI/OAI classifications mean, what’s excluded, and how to get a full 483 or EIR via FOIA.
Clinical Trial Indemnity and Insurance: What CTAs Actually Cover
How Clinical Trial Agreement indemnification and insurance clauses allocate liability between sponsors and institutions, grounded in ICH E6 sponsor obligations, and where these clauses become a real negotiation point for sponsored-programs and legal offices.
Clinical Trial Participant Payments: Structure, Ethics, and IRB Review
How and why clinical trial participants are paid, why milestone/completion-based payment structures raise undue-influence concerns under FDA and OHRP guidance, typical per-visit vs. prorated vs. lump-sum payment structures, the 2026 change to the IRS 1099 reporting threshold, and what IRBs review in a payment plan as part of protocol approval.
